In chronic HBV infection receiving nucleos(t)ide therapy, bepirovirsen vs. placebo increased treatment-free functional cure at 72 wk.

Bepirovirsen significantly increases treatment-free functional cure rates at 72 weeks in patients with chronic HBV infection on nucleos(t)ide therapy, compared to placebo.

• Why it matters: Chronic HBV infection remains a global health challenge with limited options for achieving sustained, treatment-free remission, highlighting the need for more effective therapies.
• What they did: The study involved a randomized trial comparing bepirovirsen to placebo, focusing on patients receiving nucleos(t)ide therapy, with outcomes measured at 72 weeks.
• The result: Bepirovirsen improved the rate of functional cure without ongoing treatment, suggesting it could enhance long-term management and potential remission in chronic HBV patients.